Copyright
©The Author(s) 2023.
World J Gastrointest Pathophysiol. Aug 24, 2023; 14(4): 71-85
Published online Aug 24, 2023. doi: 10.4291/wjgp.v14.i4.71
Published online Aug 24, 2023. doi: 10.4291/wjgp.v14.i4.71
Figure 4 Distal colon model: Alpha and beta diversity analyses.
MiSeq compositional sequencing and bioinformatic analysis were performed to measure the microbiota diversity changes following ADS024 treatment using the: A: Shannon index for alpha diversity; B: Simpson diversity index for alpha diversity; C: UniFrac principal coordinates analysis for beta diversity.
- Citation: Murphy CK, O’Donnell MM, Hegarty JW, Schulz S, Hill C, Ross RP, Rea MC, Farquhar R, Chesnel L. Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against Clostridioides difficile infection challenge in vivo. World J Gastrointest Pathophysiol 2023; 14(4): 71-85
- URL: https://www.wjgnet.com/2150-5330/full/v14/i4/71.htm
- DOI: https://dx.doi.org/10.4291/wjgp.v14.i4.71